Implications of Mutation Profiling in Myeloid Malignancies: PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies.
- Published in:
- Oncology (08909091), 2018, v. 32, n. 5, p. e45
- By:
- Publication type:
- Article
Works matching IS 08909091 AND DT 2018 AND VI 32 AND IP 5
Results: 9
1
2
Immunizing Cancer Patients: Which Patients? Which Vaccines? When to Give?
- Published in:
- Oncology (08909091), 2018, v. 32, n. 5, p. 254
- By:
- Publication type:
- Article
3
Robert Chapkin on relationships between the gut microbiome, diet, and colorectal cancer.
- Published in:
- Oncology (08909091), 2018, v. 32, n. 5, p. 248
- By:
- Publication type:
- Article
4
Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk Factors.
- Published in:
- Oncology (08909091), 2018, v. 32, n. 5, p. 243
- By:
- Publication type:
- Article
5
Improving Adherence to Endocrine Therapy in Women With HR-Positive Breast Cancer.
- Published in:
- Oncology (08909091), 2018, v. 32, n. 5, p. 235
- By:
- Publication type:
- Article
6
Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
- Published in:
- Oncology (08909091), 2018, v. 32, n. 5, p. 228
- By:
- Publication type:
- Article
7
COUNTERPOINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer.
- Published in:
- Oncology (08909091), 2018, v. 32, n. 5, p. 223
- By:
- Publication type:
- Article
8
POINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer.
- Published in:
- Oncology (08909091), 2018, v. 32, n. 5, p. 223
- By:
- Publication type:
- Article
9
CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor--Positive Advanced Breast Cancer?
- Published in:
- Oncology (08909091), 2018, v. 32, n. 5, p. 216
- By:
- Publication type:
- Article